MarketPulse

FDA drug rejection

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Aldeyra Stock Plummets 70% After FDA Rejection; Law Firm Eyes Securities Claims

Johnson Fistel investigates Aldeyra Therapeutics after FDA rejects lead drug reproxalap. Stock tumbles over 70% on March 17, 2026 announcement.
ALDXstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Corcept Stock Plummets 50% After FDA Rejects Key Drug; Lawsuit Probe Launched

Johnson Fistel investigates Corcept Therapeutics ($COPT) for securities violations after FDA rejected relacorilant application, triggering 50% stock decline.
CORTinvestor lossesrelacorilant